Supporting the role of these activatory pathways, in about 40% of patients, mutations on STAT3 and STAT5b have been recognized as the most common gain-of-function genetic lesions up to now identified in LGLL patients. The gene discussed is STAT5B; the disease is T-cell large granular lymphocyte leukemia.